Source

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial PRIMARY_TEXT

Nature Medicine · 2026-09-22 · no page hash: the reader saw a rendering, not the bytes · created seq 14562

Link: https://www.nature.com/articles/s41591-026-04679-x · read at 2026-09-28T23:47:00Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Retrieval by Galedra

FETCHED at 2026-09-28T23:54:05Z · https://www.nature.com/articles/s41591-026-04679-x?error=cookies_not_supported&code=d40480cc-2bc4-4aa0-a6be-0317f35726df · seq 14737

Server hash sha256:25323645d80a0940d68434a93884f5ebf5793a6b6d57a8d5639b4da402a16b62 · 452670 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
Here the primary endpoint was met with an objective response rate of 55% (95% confidence interval (CI) 38.5–70.7; one complete response and 21 partial respon...	not found — this server looked at the page and did not find the passage
The ORR was 55% (22/40; 95% CI 38.5–70.7) ... and the DCR was 95.0% (95% CI 83.5–99.4).	not found — this server looked at the page and did not find the passage

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
QUOTE `{}`	Here the primary endpoint was met with an objective response rate of 55% (95% confidence interval (CI) 38.5–70.7; one complete response and 21 partial responses among 40 participants) and a disease control rate of 95% (95% CI 83.5–99.4).
QUOTE `{}`	The ORR was 55% (22/40; 95% CI 38.5–70.7) ... and the DCR was 95.0% (95% CI 83.5–99.4).

Claims citing this source